Table 2 Hazard ratio (95% confidence interval) for the association between tumor subtype and breast cancer-specific survival among breast cancer cases in CBCS Phases 1–2, overall and stratified by estrogen receptor (ER) status.

From: Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases

Tumor subtype

Overall

ER positive

ER negative

N (events)

Minimally adjusteda

Adjustedb

N (events)

Minimally adjusteda

Adjustedb

N (events)

Minimally adjusteda

Adjustedb

RNA-based TP53

Wildtype-like

340 (59)

Ref.

Ref.

274 (50)

Ref.

Ref.

65 (9)

Ref.

Ref.

Mutant-like

363 (121)

6.94 (3.74–12.87)

7.21 (3.76–13.82)

97 (33)

5.23 (2.09–13.08)

4.66 (1.79–12.15)

265 (88)

4.81 (1.67–13.86)

5.38 (1.84–15.78)

Tc

 

0.81 (0.75–0.88)

0.81 (0.74–0.87)

 

0.87 (0.77–0.97)

0.86 (0.77–0.96)

 

0.86 (0.76–0.99)

0.88 (0.77–0.99)

DNA-based TP53

Wildtype

347 (69)

Ref.

Ref.

258 (51)

Ref.

Ref.

85 (17)

Ref.

Ref.

Mutant

247 (82)

3.57 (2.00–6.35)

3.34 (1.82–6.11)

88 (31)

4.22 (1.81–9.82)

4.06 (1.68–9.82)

156 (51)

1.81 (0.76–4.31)

1.68 (0.69–4.08)

Tc

 

0.89 (0.83–0.96)

0.89 (0.83–0.96)

 

0.89 (0.81–0.99)

0.89 (0.80–0.98)

 

0.98 (0.86–1.12)

0.99 (0.86–1.13)

IHC-based TP53

Wildtype-like

752 (156)

Ref.

Ref.

457 (83)

Ref.

Ref.

288 (71)

Ref.

Ref.

Mutant-like

533 (157)

1.66 (1.14–2.41)

1.51 (1.04–2.21)

261 (73)

2.03 (1.10–3.76)

1.77 (0.95–3.30)

267 (84)

1.24 (0.76–2.01)

1.29 (0.79–2.10)

Tc

 

0.97 (0.93–1.02)

0.97 (0.92–1.02)

 

0.96 (0.90–1.03)

0.97 (0.90–1.03)

 

1.01 (0.93–1.09)

1.00 (0.92–1.09)

PAM50 subtype

Other

473 (104)

Ref.

Ref.

345 (74)

Ref.

Ref.

127 (30)

Ref.

Ref.

Basal-like

230 (76)

3.05 (1.83–5.09)

3.37 (1.99–5.71)

26 (9)

3.62 (1.00–13.12)

3.40 (0.91–12.77)

203 (67)

1.27 (0.67–2.41)

1.66 (0.87–3.18)

Tc

 

0.86 (0.79–0.93)

0.86 (0.79–0.93)

 

0.87 (0.73–1.05)

0.87 (0.73–1.05)

 

1.00 (0.89–1.12)

0.99 (0.88–1.12)

  1. CBCS Carolina Breast Cancer Study, ER estrogen receptor, IHC immunohistochemistry, PAM50 Prediction Analysis of Microarray 50.
  2. aAdjusted for age at diagnosis (continuous), race (Black/non-Black), and study phase.
  3. bAdditionally adjusted for tumor stage, grade, size, and node status.
  4. cLog of time-varying coefficient (if T < 1 then hazard decreases with time, and if T > 1 then hazard increases with time).
Back to article page